1
Zonguldak Bülent Ecevit University, Çaycuma Food and Agriculture Vocational School, Department of Chemistry and Chemical Processing, Zonguldak
Abstract
Thyroid hormones are biological molecules that play a critical role in regulating metabolic rate and maintaining many physiological functions of the organism. Lack of iodine leads to various endocrine disorders, especially hypothyroidism. Synthetic levothyroxine (LT4) is generally preferred in the medication of hypothyroidism. LT4 is a molecule with low water solubility and high thermosensitivity. Absorption of the drug varies depending on gastric pH, integrity of the gastrointestinal mucosa and concomitant medications. Levotiron tablet samples of 100 mg and 25 mg were used in this study. The powdered tablets were first analyzed directly in FTIR-ATR and then in FTIR using KBr. Spectra were obtained in the mid-infrared region (4000-550 cm-1 and 4000-400 cm-1) with 64 scans and a resolution of 4 cm-1. The obtained spectra were peak analyzed with Origin Pro software. Savitzky-Golay smoothing and filtering method was applied during 2nd order differentiation to remove noise and background effects in the spectra. When the spectra of 25 mg samples prepared directly and with KBr pellet were examined, different intensities were found at the same peak positions. However, some peaks such as C-I appeared better in samples prepared with pellets. It is thought that derivatized spectra will support chemometric analysis in quantitative analysis studies.
ÇOLAK, S. (2025). Comparison of FTIR Spectra and Related Derivatized Spectra of Tablets Containing Levothyroxine Obtained ATR and With KBr Pellets. MAS Journal of Applied Sciences, 10(3), 438–445. https://doi.org/10.5281/zenodo.16722414
📄AlBathish, M., Gazy, A., Al Jamal, M., Bejjani, A., 2024. Utilization of the FTIR spectroscopic method for the quantitative determination of the narrow therapeutic index levothyroxine sodium in pharmaceutical tablets. Pharmacia, 71: 1–9.
📄Aleskandrany, A., Şahin, İ., 2020. The effects of levothyroxine on the structure and dynamics of DPPC liposome: FTIR and DSC studies. Biochimica et Biophysica Acta (BBA)–Biomembranes, 1862(6): 183245.
📄Azizi, F., Moeini, A.S., Mehran, L., Masumi, S., Abdi, H., Foroutan, S.M., Saghafinia, A.E., Amuzegar, A., 2025. Treatment of hypothyroidism with the combination of levothyroxine and slow-release triiodothyronine: a randomized clinical trial. Journal of Clinical and Translational Endocrinology, 40: 100395.
📄Benvenga, S., Carlé, A., 2019. Levothyroxine formulations: pharmacological and clinical ımplications of generic substitution. Advances in Therapy. 36: 59–71.
📄Candan, H., Yorulmaz, A., 2023. Evaluation of cases presenting with levothyroxine intoxication to the pediatric emergency department. Pediatric Practice and Research. 11(3): 125–129.
📄Chamelarocá, H., Catapano, M.C., Garrigues, J.C., Ŝvec, F., Novákova, L., 2024. Advancing drug safety and mitigating health concerns high-resolution mass spectrometry in the levothyroxine case study. Journal of Pharmaceutical Analysis, 14(9): 100970.
📄Colucci, P., Yue, C.S., Ducharme, M., Benvenga, S., 2013. A review of the pharmacokinetics of levothyroxine for the treat hypothyroidism. European Endocrinology, 9(1): 40.
📄Dirikoç, A., Genç, B., Özdemir, D., Tam, A.B. B.A.S., Topaloğlu, O., Ersoy, R., Çakır, B., 2021. Adherence to levothyroxine treatment and factors related with adherence in patients and hypothyroidism. Ankara Medical Journal, 21(2).
📄Gatta, E., Maltese, V., Pirola, I., Gandossi, E., Silvestrini, I., Ugoccioni, M., Cappelli, C., 2025. Are liquid levothyroxine formulations interchangeable? The LETI Study. Thyroid Research, 18(1): 17.
📄Khanam, A.A., Padmavathi, Y., Babu R., 2020. Development and validation of derivative ftır spectroscopy for estimation of entecavir monohydrate in its pure and pharmaceutical dosage forms. Global Journal of Medical Research: B Pharma, Drug Discovery, Toxicology & Medicine, 20:5.
📄Kocić, I.A., 2013. Biopharmaceutical characterization-release levothyroxine sodium tablets. Doctoral Thesis, University of Belgrade, Serbia.
📄Kokümer, M., Şehirli, A.O., 2015. Drug-induced thyroid disorders. Clinical and Experimental Health Sciences, 5(3): 191.
📄Ledeti, A., Vlase, G., Vlase, T., Matusz, P., Bercean, V., ¸Suta, L.M., Piciu, D., 2016. Thermal stability of ynthetic thyroid hormone l-thyroxine and l-thyroxine sodium salt hydrate both pure and in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 125: 33–40.
📄Ledeți, I., Romanescu, M., Cîrcioban, D., Ledeți, A., Vlase, G., Vlase, T., Suciu, O., Murariu, M., Olariu, S., Matusz, P., Buda, V., Piciu, D., 2020. Stability and compatibility studies of levothyroxine sodiumin solid binary systems—ınstrumental screening. Pharmaceutics, 12(1): 58.
📄Liu, H., Liu, W., Zhang, W., Sun, S., Chen, C., 2023. Levothyroxine: conventional novel drug delivery formulations. Endocrine Reviews. 44(3): 393–416.
📄Öcal, S., 2015. Preparation of a biocompatible carrier ımplant for controlled release of drugs used in the treatment of hyperthyroidism and hypothyroidism. Master’s thesis, Kırıkkale University, Institute of Science, Kırıkkale.
📄Pottel, J., 2020. The Activities of drug ınactive ıngredients on biological targets. Science, 369(6502): 7797-799.
📄Shaban, K., 2018. Development, characterization and evaluation of chemical stability of fast-dissolving oral levothyroxine films. Doctoral thesis, University of Brighton, Institute of Science, Brighton.
📄Sreeramoju, M.K, Digenis, G.A., May, J., 2021. Detection and characterization of an unknown impurity in levothyroxine oral solution product: implications for formulation development and storage. Journal of Pharmaceutical Sciences, 110(2): 682-686.
📄Tel, E., Sabuncuoğlu, S., 2017. Levothyroxine used in thyroid dysfunction during pregnancy and their toxicities. FABAD Journal of Pharmaceutical Sciences, 42(3): 239–248.
📄Wiesner, A., Gajewska, D., Pasko, P., 2021. Levothyroxine interactions with food and dietary supplements–a systematic review. Pharmaceuticals, 14(3): 206.
📄Yılmaz, N., 2006. Preparation and evaluation of a transdermal therapeutic system containing l-thyroxine sodium. Master’s thesis, Marmara University, Institute of Science, Istanbul.